术前新辅助化疗对直肠癌肝转移患者近期疗效及远期生存率的影响  

Effect of preoperative neoadjuvant chemotherapy on short-term efficacy and long-term survival rate of patients with liver metastasis from rectal cancer

作　　者：焦移乐 马骏 JIAO Yi-le;MA Jun(the Second Affiliated Hospital of Shaanxi University of Chinese Medicine,Xianyang 712000;Xi'an Gaoxin Hospital,Xi'an 710077,China)

机构地区：[1]陕西中医药大学第二附属医院,陕西咸阳712000 [2]西安高新医院,陕西西安710077

出　　处：《临床医学研究与实践》2019年第1期11-12,15,共3页Clinical Research and Practice

摘　　要：目的术前新辅助化疗对直肠癌肝转移患者近期疗效及远期生存率的影响。方法回顾性分析我院2012—2015年收治的95例直肠癌肝转移患者的临床资料,患者均行肝切除,按照治疗方法的不同将其分为试验组(56例,术前接受新辅助化疗)和对照组(39例,术前未接受化疗)。比较两组患者近期疗效及远期生存率。结果两组患者的手术时间比较,差异无统计学意义(P>0.05);试验组的术中出血量少于对照组,差异具有统计学意义(P<0.05);试验组术后7 d的AST及ALT水平均高于对照组,差异具有统计学意义(P<0.05)。两组患者的不良反应总发生率比较,差异无统计学意义(P>0.05)。本研究95例患者的中位生存时间为35个月,两组患者的中位生存时间比较,差异无统计学意义(P>0.05)。结论术前新辅助化疗并未使得直肠癌肝转移患者生存获益,反而可能增加患者的肝损害。Objective To investigate the effect of preoperative neoadjuvant chemotherapy on short-term efficacy and long-term survival rate of patients with liver metastasis from rectal cancer.Methods The clinical data of 95 patients with liver metastasis from rectal cancer admitted in our hospital from 2012-2015 were retrospectively analyzed.All patients underwent hepatectomy, they were divided into experimental group (56 cases, received neoadjuvant chemotherapy before operation) and control group (39 cases, no preoperative chemotherapy).The short-term efficacy and long-term survival rate of the two groups were compared.Results There was no significant difference in the length of operation between the two groups (P>0.05); the amount of intraoperative blood loss in the experimental group was less than that in the control group (P<0.05); the levels of AST and ALT in the experimental group at 7 days after operation were higher than those in the control group (P<0.05).There was no significant difference in the total incidences of adverse reactions between the two groups (P>0.05).The median survival time of 95 patients in this study was 35 months, there was no significant difference in median survival time between the two groups (P>0.05).Conclusion Preoperative neoadjuvant chemotherapy does not benefit the survival of patients with liver metastasis from rectal cancer, but may increase liver damage.

关 键 词：术前新辅助化疗 直肠癌肝转移 生存率 

分 类 号：R734.2[医药卫生—肿瘤]